Document:

Exhibit 10.1

 

PURCHASE AGREEMENT

 

PURCHASE AGREEMENT (the
 “Agreement”), dated as of December 28, 2022, by and between NEUBASE THERAPEUTICS, INC., a Delaware corporation (the “Company”),
and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”).

 

RECITALS

 

WHEREAS, subject to
the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from
the Company, up to $3,000,000 in registered shares of the Company’s Common Stock, par value $0.0001 per share (the “Common
Stock”). The shares of Common Stock to be acquired hereunder are referred to herein as the “Securities.”

 

NOW THEREFORE, in
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the Company and the Investor hereby agree as follows:

 

ARTICLE I

CERTAIN DEFINITIONS

 

Section 1.1           
DEFINED TERMS. As used in this Agreement, the following terms shall have the following meanings specified or indicated (such
meanings to be equally applicable to both the singular and plural forms of the terms defined):

 

“Affiliate”
shall mean, with respect to a Party, any individual, a corporation or any other legal entity, directly or indirectly, controlling, controlled
by or under common control with such Party. For purpose of this definition, the term “control,” as used with respect
to any corporation or other entity, means (a) direct or indirect ownership of fifty percent (50%) or more of the securities or other ownership
interests representing the equity voting stock or general partnership or membership interest of such corporation or other entity or (b)
the power to direct or cause the direction of the management or policies of such corporation or other entity, whether through the ownership
of voting securities, by contract or otherwise.

 

“Agreement”
shall have the meaning specified in the preamble hereof.

 

“Average Daily Trading
Volume” shall mean the median daily trading volume of the Company’s Common Stock over the most recent five (5) Business
Days prior to the respective Purchase Notice Date.

 

“Bankruptcy Law”
means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

 

“Base Registration
Statement” shall have the meaning specified in Section 4.14.

 

“Beneficial Ownership
Limitation” shall have the meaning specified in Section 7.2(g).

 

“Business Day”
shall mean a day on which the Principal Market shall be open for business for trading from the hours of 9:30 am until 4:00 pm eastern
time.

 

    

     

    

 

“Clearing Costs”
shall mean all of the Investor’s reasonable and documented broker and Transfer Agent costs with respect to the deposit of the Purchase
Notice Shares.

 

“Closing”
shall mean any one of the closings of a purchase and sale of shares of Common Stock pursuant to Section 2.2.

 

“Closing Date”
shall mean the date a Closing occurs.

 

“Commitment Period”
shall mean the period commencing on the Execution Date and ending on the earlier of (i) the second anniversary of the execution of this
Agreement, or (ii) the date on which the Investor shall have purchased Purchase Notice Shares pursuant to this Agreement for an aggregate
purchase price of the Investment Amount.

 

“Commitment Shares”
means shares of the Company’s Common Stock to be issued by the Company to the Investor pursuant to Section 6.4.

 

“Common Stock”
shall mean the Company’s common stock, par value $0.0001 per share.

 

“Common Stock Equivalents”
means any securities of the Company entitling the holder thereof to acquire at any time Common Stock, including, without limitation, any
debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company”
shall have the meaning specified in the preamble to this Agreement.

 

“Custodian”
means any receiver, trustee, assignee, liquidator, or similar official under any Bankruptcy Law.

 

“Current Report”
has the meaning set forth in Section 6.2.

 

“Damages”
shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, attorneys’ fees and disbursements
and costs and expenses of expert witnesses and investigation that are (i) actually and reasonably paid or incurred, and (ii) documented,
so long as no Party shall be required to provide any documentation or information to the extent
that the provision thereof would undermine or otherwise jeopardize attorney-client privilege).

 

“DTC” shall
mean The Depository Trust Company, or any successor performing substantially the same function for the Company.

 

“DTC/FAST Program”
shall mean the DTC’s Fast Automated Securities Transfer Program.

 

“DWAC”
shall mean Deposit Withdrawal at Custodian as defined by the DTC.

 

“DWAC Eligible”
shall mean that (a) the Common Stock is eligible at DTC for full services pursuant to DTC’s operational arrangements, including,
without limitation, transfer through DTC’s DWAC system, (b) the Company has been approved (without revocation) by the DTC’s
underwriting department, (c) the Transfer Agent is approved as an agent in the DTC/FAST Program, (d) the Purchase Notice Shares and Commitment
Shares are otherwise eligible for delivery via DWAC, and (e) the Transfer Agent does not have a policy prohibiting or limiting delivery
of the Purchase Notice Shares and Commitment Shares, as applicable, via DWAC.

 

    2

     

    

 

“DWAC Shares”
means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on
resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified DWAC account with DTC under
the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

“Exchange Act”
shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exchange Cap”
shall have the meaning set forth in Section 7.2(h).

 

“Execution Date”
shall mean the date of the last signature of this Agreement.

 

“Increase Commitment
Shares” means shares of the Company’s Common Stock, in an amount equal to two percent (2%) of any increase in Investment
Amount pursuant to Section 2.1(b) divided by the VWAP of the Common Stock for the five (5) Business Days preceding the date of
issuance and delivery of the Increase Commitment Shares, to be issued by the Company to the Investor pursuant to Section 6.4.

 

“Investment Amount”
shall initially mean $3,000,000, subject to increase as set forth in Section 2.1(b).

 

“Investor”
shall have the meaning specified in the preamble to this Agreement.

 

“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other restriction.

 

“Material Adverse
Effect” shall mean any effect on the business, operations, properties, or financial condition of the Company that is material
and adverse to the Company and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with
the ability of the Company to enter into and perform its obligations under any Transaction Document.

 

“Party”
shall mean a party to this Agreement.

 

“Person”
shall mean an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality thereof.

 

“Principal Market”
shall mean any of the national exchanges (i.e., NYSE, AMEX, Nasdaq), or principal quotation systems (i.e., OTCQX, OTCQB, OTC Pink, the
OTC Bulletin Board), or other principal exchange or recognized quotation system which is at the time the principal trading platform or
market for the Common Stock.

 

    3

     

    

 

“Purchase Notice
Amount” shall mean the Purchase Notice Shares referenced in the Purchase Notice multiplied by the Purchase Price in accordance
with Section 2.1.

 

“Purchase Notice”
shall mean a written notice from Company, substantially in the form of Exhibit A hereto, to the Investor setting forth the Purchase
Notice Shares which the Company requires the Investor to purchase pursuant to the terms of this Agreement.

 

“Purchase Notice
Date” shall have the meaning specified in Section 2.2(a).

 

“Purchase Notice
Limitation” shall mean a limitation of $500,000 per Purchase Notice; provided, however, that the Parties may mutually agree,
in writing, to increase the Purchase Notice limitation to an amount not to exceed $1,000,000 per Purchase Notice.

 

“Purchase Notice
Shares” shall mean all shares of Common Stock that the Company shall be entitled to issue as set forth in all Purchase Notices
in accordance with the terms and conditions of this Agreement.

 

“Purchase Price”
shall mean the lowest traded price of the Common Stock during the three (3) Business Days immediately prior to the Closing Date multiplied
by 95%.

 

“Registration Statement”
shall have the meaning specified in Section 6.3.

 

“Regulation D”
shall mean Regulation D promulgated under the Securities Act.

 

“Rule 144”
shall mean Rule 144 under the Securities Act or any similar provision then in force under the Securities Act.

 

“SEC” shall
mean the United States Securities and Exchange Commission.

 

“SEC Documents”
shall have the meaning specified in Section 4.5.

 

“Securities”
mean the Purchase Notice Shares and the Commitment Shares to be issued to the Investor pursuant to the terms of this Agreement.

 

“Securities Act”
shall mean the Securities Act of 1933, as amended.

 

“Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock
or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the
Securities Act.

 

“Transaction Documents”
shall mean this Agreement and all exhibits hereto and thereto.

 

“Transfer Agent”
shall mean the current transfer agent of the Company, and any successor transfer agent of the Company.

 

“VWAP”
means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or, if the
Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market
on which such security is then traded), during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time,
as determined by the Investor or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter
market on the electronic bulletin board for such security during the period beginning at 9:30 a.m., New York time, and ending at 4:00
p.m., New York time, as determined by the Investor, or, if no dollar volume-weighted average price is reported, the average of the highest
closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets”
by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security on such date on any of the foregoing
bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Investor. If
the Company and the Investor are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance
with the procedures in Section 10.15. All such determinations shall be appropriately adjusted for any share dividend, share split, share
combination, recapitalization, or other similar transaction during such period.

 

    4

     

    

 

ARTICLE II

PURCHASE AND SALE OF COMMON STOCK

 

Section 2.1           
PURCHASE NOTICES.

 

(a)              
Purchase NoticeS. Subject to the conditions set forth herein, at any time
during the Commitment Period, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the
Investor of a Purchase Notice from time to time, to purchase the number of Purchase Notice Shares set forth on the Purchase Notice at
the Purchase Price, provided that the amount of Purchase Notice Shares shall not exceed the Purchase Notice Limitation applicable to such
Purchase Notice or the Beneficial Ownership Limitation set forth in Section 7.2(g). The Company may not deliver a subsequent Purchase
Notice until the Closing of an active Purchase Notice, except if waived by the Investor in writing.

 

(b)              
OPTION TO INCREASE INVESTMENT AMOUNT. At any time before the end of the Commitment Period, the Company shall have the right,
but not the obligation, to increase the Investment Amount to an amount not to exceed $10,000,000 in the aggregate by providing written
notice of the Company’s election to increase the Investment Amount, which shall include the amount of the increase and the revised
aggregate Investment Amount, to the Investor by email and by overnight courier at its address set forth in Section 10.16. Such increase
in Investment Amount shall become effective upon the Company’s issuance and delivery to Investor of additional Commitment Shares
pursuant to Section 6.4.

 

Section 2.2           
MECHANICS.

 

(a)              
PURCHASE NOTICE. In accordance with Section 2.1 and subject to the satisfaction of the conditions set forth in Section 7.2,
the Company shall deliver the Purchase Notice Shares as DWAC Shares to the Investor alongside the delivery of each Purchase Notice by
email and by overnight courier at its address set forth in Section 10.16. A Purchase Notice shall be deemed delivered on (i) the Business
Day that both the Purchase Notice Shares are received and the Purchase Notice has been received by email by the Investor if both conditions
are met on or prior to 8:00 a.m. New York time or (ii) the next Business Day if the conditions are met after 8:00 a.m. New York time on
a Business Day or at any time on a day which is not a Business Day (the “Purchase Notice Date”).

 

    5

     

    

 

(b)              
DELIVERY OF PURCHASE NOTICE SHARES. No later than 8:00 a.m. New York time on the Business Day of the Purchase Notice Date,
the Company shall deliver the Purchase Notice Shares as DWAC Shares to the Investor.

 

(c)              
CLOSING. The Closing of a Purchase Notice shall occur no later than three (3) Business Days after a Purchase Notice Date.
The Investor shall deliver the Investment Amount corresponding to such Purchase Notice by wire transfer of immediately available funds
to an account designated by the Company one (1) Business Day after the Closing Date. In addition, on or prior to such Closing, each of
the Company and the Investor shall deliver to each other all documents, instruments, and writings required to be delivered or reasonably
requested by either of them pursuant to this Agreement in order to implement and effect the transactions contemplated herein.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF INVESTOR

 

The Investor represents and
warrants the following to the Company:

 

Section 3.1           
INTENT. The Investor is entering into this Agreement for its own account and the Investor has no present arrangement (whether
or not legally binding) at any time to sell the Securities to or through any Person in violation of the Securities Act or any applicable
state securities laws; provided, however, that the Investor reserves the right to dispose of the Securities at any time
in accordance with federal and state securities laws applicable to such disposition.

 

Section 3.2           
NO LEGAL ADVICE FROM THE COMPANY. The Investor acknowledges that it has had the opportunity to review this Agreement and
the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely
on such counsel and advisors and not on any statements or representations of the Company or any of its representatives or agents for legal,
tax or investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any
jurisdiction.

 

Section 3.3           
ACCREDITED INVESTOR. The Investor is an accredited investor as defined in Rule 501(a)(3) of Regulation D, and the Investor
has such experience in business and financial matters that it is capable of evaluating the merits and risks of an investment in Securities.
The Investor acknowledges that an investment in the Securities is speculative and involves a high degree of risk.

 

Section 3.4           
AUTHORITY. The Investor has the requisite power and authority to enter into and perform its obligations under the Transaction
Documents and to consummate the transactions contemplated hereby and thereby. The execution and delivery of the Transaction Documents
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action and no
further consent or authorization of the Investor is required. The Transaction Documents to which it is a party has been duly executed
by the Investor, and when delivered by the Investor in accordance with the terms hereof, will constitute the valid and binding obligation
of the Investor enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, or similar laws relating
to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application.

 

    6

     

    

 

Section 3.5           
NOT AN AFFILIATE. The Investor is not an officer, director or “affiliate” (as that term is defined in Rule 405
of the Securities Act) of the Company.

 

Section 3.6           
ORGANIZATION AND STANDING. The Investor is an entity duly formed, validly existing, and in good standing under the laws
of the State of Delaware with full right and limited partnership or similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents.

 

Section 3.7           
ABSENCE OF CONFLICTS. The execution and delivery of the Transaction Documents and the consummation of the transactions contemplated
hereby and thereby and compliance with the requirements hereof and thereof, will not (a) violate any law, rule, regulation, order, writ,
judgment, injunction, decree or award binding on the Investor, (b) violate any provision of any indenture, instrument or agreement to
which the Investor is a party or is subject, or by which the Investor or any of its assets is bound, or conflict with or constitute a
material default thereunder, (c) result in the creation or imposition of any lien pursuant to the terms of any such indenture, instrument
or agreement, or constitute a breach of any fiduciary duty owed by the Investor to any third party, or (d) require the approval of any
third-party (that has not been obtained) pursuant to any material contract, instrument, agreement, relationship or legal obligation to
which the Investor is subject or to which any of its assets, operations or management may be subject.

 

Section 3.8           
DISCLOSURE; ACCESS TO INFORMATION. The Investor had an opportunity to review copies of the SEC Documents filed on behalf
of the Company and has had access to all publicly available information with respect to the Company.

 

Section 3.9           
MANNER OF SALE. At no time was the Investor presented with or solicited by or through any leaflet, public promotional meeting,
television advertisement or any other form of general solicitation or advertising.

 

Section 3.10       
EFFECTIVE REGISTRATION STATEMENT. The Purchase Notice Shares and the Commitment Shares are being offered pursuant to the
Base Registration Statement, the Prospectus, and the Prospectus Supplement (all as defined herein), and Investor is solely relying on
the Registration Statement, the Prospectus, the Prospectus Supplement, and the SEC Documents, in determining whether to acquire the Securities.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except as set forth in the
SEC Documents, the Company represents and warrants the following to the Investor, as of the Execution Date:

 

Section 4.1           
ORGANIZATION OF THE COMPANY. The Company is an entity duly incorporated, validly existing, and in good standing under the
laws of the State of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on its business
as currently conducted. The Company is not in violation or default of any of the provisions of its amended and restated certificate of
incorporation or amended and restated bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign corporation
in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a
Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such power and authority or qualification. The Company has no Subsidiaries.

 

    7

     

    

 

Section 4.2           
AUTHORITY. The Company has the requisite corporate power and authority to enter into and perform its obligations under the
Transaction Documents. The execution and delivery of the Transaction Documents by the Company and the consummation by it of the transactions
contemplated hereby and thereby have been duly authorized by all necessary corporate action and no further consent or authorization of
the Company or its Board of Directors or stockholders is required. The Transaction Documents have been duly executed and delivered by
the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally
the enforcement of, creditors’ rights and remedies or by other equitable principles of general application.

 

Section 4.3           
CAPITALIZATION. As of the date hereof, the authorized capital stock of the Company consists of 250,000,000 shares of Common
Stock, par value $0.0001 per share, of which 33,088,657 shares are issued and outstanding, and 10,000,000 shares of Preferred Stock, par
value $0.0001 per share, of which no shares are issued and outstanding. The Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options or the vesting of restricted
stock units under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of
the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Documents
and this Agreement, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right
to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities
will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not
result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 

Section 4.4           
LISTING AND MAINTENANCE REQUIREMENTS. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of
the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such registration.

 

    8

     

    

 

Section 4.5           
SEC DOCUMENTS; DISCLOSURE. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) thereof, for the one (1)
year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the
 “SEC Documents”) on a timely basis or has received a valid extension of such time of filing and has filed any such
SEC Documents prior to the expiration of any such extension. As of their respective dates, the SEC Documents complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and other federal laws, rules and regulations
applicable to such SEC Documents, and none of the SEC Documents when filed contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The financial statements of the Company included in the SEC Documents comply as to form and
substance in all material respects with applicable accounting requirements and the published rules and regulations of the SEC or other
applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis during the periods involved (except (a) as may be otherwise indicated in such financial
statements or the notes thereto or (b) in the case of unaudited interim statements, to the extent they may not include footnotes or may
be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates
thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments). Except with respect to the material terms and conditions of the transactions contemplated by
the Transaction Documents, the Company confirms that neither it nor, to its knowledge, any other Person acting on its behalf has provided
the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information.
The Company understands and confirms that the Investor will rely on the foregoing representation in effecting transactions in securities
of the Company.

 

Section 4.6           
VALID ISSUANCES. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid, and non-assessable, free and clear of all Liens imposed by the Company other than
restrictions on transfer provided for in the Transaction Documents.

 

Section 4.7           
NO CONFLICTS. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by
the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Purchase Notice Shares
and Commitment Shares, do not and will not: (a) result in a violation of the Company’s amended and restated certificate of incorporation
or amended and restated bylaws, (b) conflict with, or constitute a material default (or an event that with notice or lapse of time or
both would become a material default) under, result in the creation of any Lien upon any of the properties or assets of the Company, or
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, instrument or any “lock-up”
or similar provision of any underwriting or similar agreement to which the Company is a party, or (c) result in a violation of any federal,
state or local law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable
to the Company or by which any property or asset of the Company is bound or affected (except for such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect)
nor is the Company otherwise in violation of, conflict with or in default under any of the foregoing. The business of the Company is not
being conducted in violation of any law, ordinance or regulation of any governmental entity, except for possible violations that either
singly or in the aggregate do not and will not have a Material Adverse Effect. The Company is not required under federal, state or local
law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental
agency in order for it to execute, deliver or perform any of its obligations under the Transaction Documents (other than any SEC, or state
securities filings that may be required to be made by the Company in connection with the issuance of Commitment Shares or subsequent to
any Closing or any registration statement that may be filed pursuant hereto); provided that, for purposes of the representation made in
this sentence, the Company is assuming and relying upon the accuracy of the relevant representations and agreements of Investor herein.

 

    9

     

    

 

Section 4.8           
NO MATERIAL ADVERSE EFFECT. To the Company’s knowledge, no event has occurred that would have a Material Adverse Effect
on the Company that has not been disclosed in subsequent SEC Documents.

 

Section 4.9           
LITIGATION AND OTHER PROCEEDINGS. Except as disclosed in the SEC Documents, there are no material actions, suits, investigations,
SEC inquiries, FINRA inquiries, NASDAQ inquiries, or similar proceedings (however any governmental agency may name them) pending or, to
the actual knowledge of the Company, threatened against or affecting the Company or its properties, nor has the Company received any written
or oral notice of any such action, suit, proceeding, SEC inquiry, FINRA inquiry, NASDAQ inquiry or investigation, which would have a Material
Adverse Effect. No judgment, order, writ, injunction or decree or award against the Company has been issued by or, to the actual knowledge
of the Company, requested of any court, arbitrator or governmental agency which would have a Material Adverse Effect. There has not been,
and to the actual knowledge of the Company, there is no pending investigation by the SEC involving the Company or any current officer
or director of the Company.

 

Section 4.10       
ACKNOWLEDGMENT REGARDING INVESTOR’S PURCHASE OF SECURITIES. Based solely on the Investor’s representation and
warranties, the Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm’s length purchaser
with respect to this Agreement and the transactions contemplated hereby and thereby and that the Investor is not (i) an officer or director
of the Company, or (ii) an “affiliate” (as defined in Rule 144) of the Company. The Company further acknowledges that the
Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement
and the transactions contemplated hereby and thereby, and any advice given by the Investor or any of its representatives or agents in
connection with the Agreement and the transactions contemplated hereby and thereby is merely incidental to the Investor’s purchase
of the Purchase Notice Shares. The Company further represents to the Investor that the Company’s decision to enter into this Agreement
has been based solely on the independent evaluation by the Company and its representatives.

 

    10

     

    

 

Section 4.11       
NO GENERAL SOLICITATION. Neither the Company, nor any Person acting on its behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D under the Securities act) in connection with the offer or sale of the Securities.

 

Section 4.12       
NO INTEGRATED OFFERING. None of the Company, its Affiliates, and any Person acting on their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings for purposes of any applicable stockholder approval provisions, including, without
limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company
are listed or designated, but excluding stockholder consents required to authorize and issue the Securities or waive any anti-dilution
provisions in connection therewith.

 

Section 4.13       
PLACEMENT AGENT; OTHER COVERED PERSONS. The Company has not engaged any Person to act as a placement agent, underwriter,
broker, dealer, or finder in connection with the sale of the Securities hereunder. The Company is not aware of any Person that has been
or will be paid (directly or indirectly) remuneration for solicitation of the Investor in connection with the sale of any Securities.

 

Section 4.14       
REGISTRATION STATEMENT. The Company has prepared and filed a Registration Statement on Form S-3 with the SEC in accordance
with the provisions of the Securities Act, which was declared effective by order of the SEC on April 14, 2021 (File No. 333-254980) (the
 “Base Registration Statement”). The Base Registration Statement is effective under the Securities Act and the Company
has not received any written notice that the SEC has issued or intends to issue a stop order or other similar order with respect to the
Base Registration Statement or the prospectus contained therein (the “Prospectus”), or that the SEC otherwise has (i)
suspended or withdrawn the effectiveness of the Base Registration Statement or (ii) issued any order preventing or suspending the use
of the Prospectus or any prospectus supplement thereto, in either case, either temporarily or permanently or intends or has threatened
in writing to do so. The “Plan of Distribution” section of the Prospectus permits the issuance of the Securities hereunder.
The SEC has not notified the Company of any objection to the use of the form of the Base Registration Statement pursuant to Rule 401(g)(1)
of the Securities Act. The Company was at the time of the filing of the Base Registration Statement eligible to use Form S-3. As
of the Execution Date, the Company is currently eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of the Securities that may be issued pursuant to this Agreement and during the twelve (12)
months prior to this Agreement, as set forth in General Instruction I.B.6 of Form S-3. All corporate action required to be taken
for the authorization, issuance, and sale of the Securities has been duly and validly taken. The Securities conform in all material respects
to all statements with respect thereto contained in the Base Registration Statement, the Prospectus and the Prospectus Supplement (as
defined below).

 

    11

     

    

  

ARTICLE V

COVENANTS OF INVESTOR

 

Section 5.1           
SHORT SALES AND CONFIDENTIALITY. Neither the Investor, nor any Affiliate of the Investor acting on its behalf or pursuant
to any understanding with it, will execute any short sales during the period from the Execution Date to the end of the Commitment Period.
For the purposes hereof, and in accordance with Regulation SHO, the sale after delivery of the Purchase Notice of such number of shares
of Common Stock reasonably expected to be purchased under the Purchase Notice shall not be deemed a short sale. The Investor shall, until
such time as the transactions contemplated by the Transaction Documents are publicly disclosed by the Company in accordance with the terms
of the Transaction Documents, maintain the confidentiality of the existence and terms of this transaction and the information included
in the Transaction Documents.

 

Section 5.2           
COMPLIANCE WITH LAW; TRADING IN SECURITIES. The Investor’s trading activities with respect to shares of Common Stock
will be in compliance with all applicable state and federal securities laws and regulations and the rules and regulations of the Principal
Market.

 

ARTICLE VI

COVENANTS OF THE COMPANY

 

Section 6.1           
LISTING OF COMMON STOCK. The Company shall use its commercially reasonable efforts to continue the listing or quotation
and trading of the Common Stock on the Principal Market (including, without limitation, maintaining sufficient net tangible assets, if
required) and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
the Principal Market.

 

Section 6.2           
FILING OF CURRENT REPORT. The Company agrees that it shall file a Current Report on Form 8-K, including the Transaction
Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the execution of the transactions
contemplated by, and describing the material terms and conditions of, the Transaction Documents (the “Current Report”).
The Company shall permit the Investor to review and comment upon the final pre-filing draft version of the Current Report at least two
(2) Business Days prior to its filing with the SEC, and the Company shall give reasonable consideration to all such comments. The Investor
shall use its commercially reasonable efforts to comment upon the final pre-filing draft version of the Current Report within one (1)
Business Day from the date the Investor receives it from the Company.

 

Section 6.3           
FILING OF REGISTRATION STATEMENT. The Company shall file with the SEC, within two (2) Business Days from the Execution Date,
a prospectus supplement covering the offering and sale of the Purchase Notice Shares (the “Prospectus Supplement”). The Prospectus
Supplement shall relate to the transactions contemplated by, and describing the material terms and conditions of, this Agreement, containing
required information previously omitted from the Prospectus at the time of effectiveness of the Base Registration Statement in reliance
on Rule 430B under the Securities Act, and disclosing all information relating to the transactions contemplated hereby required to be
disclosed in the Base Registration Statement and the Prospectus as of the date of the Prospectus Supplement, including, without limitation,
information required to be disclosed in the section captioned “Plan of Distribution” in the Prospectus. The Company shall
permit the Investor to review and comment upon the Prospectus Supplement within a reasonable time prior to their filing with the SEC and
the Company shall give reasonable consideration to all such comments. The Investor shall furnish to the Company such information regarding
itself, the Company’s securities beneficially owned by the Investor, and the intended method of distribution thereof, including
any arrangement between the Investor and any other person or relating to the sale or distribution of the Company’s securities, as
shall be reasonably requested by the Company in connection with the preparation and filing of the Current Report and the Prospectus Supplement,
and shall otherwise cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of
the Current Report and the Prospectus Supplement with the SEC. At the time of the filing of the Prospectus Supplement, the Company shall
have no knowledge of any untrue statement (or alleged untrue statement) of a material fact in the Prospectus (as supplemented by the Prospectus
Supplement) or omission (or alleged omission) of a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading, and there shall be no such untrue statement of material fact
or omission in any effective registration statement filed or any post-effective amendment or prospectus which is a part of the foregoing.
The Company shall promptly give the Investor notice of any event (including the passage of time) which makes the Prospectus not to be
in compliance with Section 5(b) or 10 of the Securities Act and shall use its best efforts thereafter to file with the SEC any post-effective
amendment to the Base Registration Statement, amended Prospectus or Prospectus Supplement in order to comply with Section 5(b) or 10 of
the Securities Act.

 

    12

     

    

 

Section 6.4           
 ISSUANCE OF COMMITMENT SHARES. In consideration for the Investor’s execution and delivery of, and performance under
this Agreement, the Company shall cause the Transfer Agent to issue Commitment Shares to the Investor as follows:

 

(a)              
Commitment Shares in an amount equal to one percent (1%) of the Investment Amount divided by the closing price of the Common Stock
on the Execution Date of this Agreement, within two (2) Business Days of the filing of the Prospectus Supplement with the SEC, which issuance
shall be evidenced by one or more book-entry statement(s) reflecting the shares in the name of the Investor or its designee.

 

(b)              
Commitment Shares in an amount equal to one-half of one percent (0.5%) of the Investment Amount divided by the closing price of
the Common Stock on the third Business Day prior to the date of issuance and delivery of said Commitment Shares, on the first anniversary
of the Execution Date of this Agreement, which issuance shall be evidenced by one or more book-entry statement(s) reflecting the shares
in the name of the Investor or its designee.

 

(c)              
Commitment Shares in an amount equal to one-half of one percent (0.5%) of the Investment Amount divided by the closing price of
the Common Stock on the third Business Day prior to the date of issuance and delivery of said Commitment Shares, on the date of expiration
of this Agreement, which issuance shall be evidenced by one or more book-entry statement(s) reflecting the shares in the name of the Investor
or its designee.

 

If the Company elects to increase
the Investment Amount pursuant to Section 2.1(b), the Company shall cause the Transfer Agent to issue Increase Commitment Shares (based
on each increase of Investment Amount) to the Investor within five (5) Business Days of the Company’s written notice of the election,
which issuance shall be evidenced by one or more book-entry statement(s) reflecting the shares in the name of the Investor or its designee.
Any and all such book-entry statement(s) shall be delivered to the Investor by overnight courier at its address set forth in Section 10.16.

 

Section 6.5        
LOCK-UP. The Investor agrees that in connection with any public offering of securities by the Company, the Investor will
not transfer, make any short sale of, loan, grant any option for the purchase of, pledge, enter into any swap or other arrangement that
transfers any of the economic ownership, or otherwise encumber or dispose of any portion of any Common Stock or other securities of the
Company then held by the Investor for a period, not to exceed 180 days, as may be requested by the Company. The Investor also agrees that
he or she will sign a “lock up” or similar arrangement in connection with a public offering on terms and conditions that the
Company or the managing underwriter(s) thereof deems necessary or desirable for a period not to exceed 180 days. While such lock up arrangement
is in effect, the Company may not submit any Purchase Notices to the Investor unless mutually waived between the Investor and the Company.

 

    13

     

    

 

ARTICLE VII

CONDITIONS TO DELIVERY OF

PURCHASE NOTICE AND CONDITIONS TO CLOSING

 

Section 7.1           
CONDITIONS PRECEDENT TO THE OBLIGATION OF THE COMPANY TO ISSUE AND SELL PURCHASE NOTICE SHARES. The obligation of the Company
to issue and sell the Purchase Notice Shares to the Investor is subject to the satisfaction of each of the conditions set forth below:

 

(a)              
ACCURACY OF INVESTOR’S REPRESENTATIONS AND WARRANTIES. The representations and warranties of the Investor shall be
true and correct in all material respects as of the Execution Date and as of the date of each Closing as though made at each such time.

 

(b)              
PERFORMANCE BY INVESTOR. Investor shall have performed, satisfied and complied in all respects with all covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to each Closing.

 

(c)              
PRINCIPAL MARKET REGULATION. The Company shall have no obligation to issue any Purchase Notice Shares, and the Investor
shall have no right to receive any Purchase Notice Shares, if the issuance of such Purchase Notice Shares would exceed the aggregate number
of shares of Common Stock which the Company may issue without breaching the Company’s obligations under the rules or regulations
of the Principal Market.

 

Section 7.2           
CONDITIONS PRECEDENT TO THE OBLIGATION OF INVESTOR TO PURCHASE THE PURCHASE NOTICE SHARES. The obligation of the Investor
hereunder to purchase the Purchase Notice Shares is subject to the satisfaction of each of the following conditions:

 

(a)              
EFFECTIVE REGISTRATION STATEMENT. The Base Registration Statement, and any amendment or supplement thereto, shall remain
effective for the offering and sale of the Purchase Notice Shares and (i) the Company shall not have received notice that the SEC has
issued or intends to issue a stop order with respect to such Base Registration Statement or that the SEC otherwise has suspended or withdrawn
the effectiveness of such Base Registration Statement, either temporarily or permanently, or intends or has threatened to do so and (ii)
no other suspension of the use of, or withdrawal of the effectiveness of, such Base Registration Statement, the Prospectus or the Prospectus
Supplement shall exist. The Investor shall not have received any notice from the Company that the Prospectus, Prospectus Supplement or
amendment thereto fails to meet the requirements of Section 5(b) or Section 10 of the Securities Act.

 

    14

     

    

 

(b)              
ACCURACY OF THE COMPANY’S REPRESENTATIONS AND WARRANTIES. The representations and warranties of the Company shall
be true and correct in all material respects as of the date of this Agreement and as of the date of each Closing (except for representations
and warranties specifically made as of a particular date).

 

(c)              
PERFORMANCE BY THE COMPANY. The Company shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company.

 

(d)              
NO INJUNCTION. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits or directly and materially adversely
affects any of the transactions contemplated by the Transaction Documents, and no proceeding shall have been commenced that may have the
effect of prohibiting or materially adversely affecting any of the transactions contemplated by the Transaction Documents.

 

(e)              
ADVERSE CHANGES. Since the date of filing of the Company’s most recent annual report on Form 10-K or Quarterly Report
on Form 10-Q (whichever is later), no event that had or is reasonably likely to have a Material Adverse Effect has occurred and be continuing.

 

(f)               
NO SUSPENSION OF TRADING IN OR DELISTING OF COMMON STOCK. The trading of the Common Stock shall not have been suspended
by the SEC or the Principal Market, or otherwise halted for any reason, and the Common Stock shall have been approved for listing or quotation
on and shall not have been delisted from or no longer quoted on the Principal Market. If a suspension, delisting, or halting for any reason,
of the trading of the Common Stock, as contemplated by this Section 7.2(f), occurs after the delivery of a Purchase Notice but
before the Closing with respect to such Purchase Notice, and such suspension, delisting, or halting, as applicable, is not lifted within
48 hours of its implementation, the Investor shall have the right to refuse to purchase the amount of Purchase Notice Shares associated
with such Purchase Notice, return to the Company the amount of Purchase Notice Shares associated with such Purchase Notice, and the Investment
Amount with respect to such Purchase Notice Shares so refused or returned shall be refunded accordingly.

 

    15

     

    

 

(g)              
BENEFICIAL OWNERSHIP LIMITATION. The number of Purchase Notice Shares then to be purchased by the Investor shall not exceed
the number of such shares that, when aggregated with all other shares of Common Stock then owned by the Investor beneficially or deemed
beneficially owned by the Investor, would result in the Investor owning more than the Beneficial Ownership Limitation (as defined below),
as determined in accordance with Section 13 of the Exchange Act. For purposes of this Section 7.2(g), if the amount of Common Stock
outstanding is greater or lesser on a Closing Date than on the date upon which the Purchase Notice associated with such Closing Date is
given, the amount of Common Stock outstanding on such issuance of a Purchase Notice shall govern for purposes of determining whether the
Investor, when aggregating all purchases of Common Stock made pursuant to this Agreement, would own more than the Beneficial Ownership
Limitation following a purchase on any such Closing Date. If the Investor claims that compliance with a Purchase Notice would result in
the Investor owning more than the Beneficial Ownership Limitation, upon request of the Company the Investor will provide the Company with
evidence of the Investor’s then existing shares beneficially or deemed beneficially owned. The “Beneficial Ownership Limitation”
shall be 9.99% of the number of shares of the Common Stock outstanding immediately prior to the issuance of shares of Common Stock issuable
pursuant to a Purchase Notice. To the extent that the Beneficial Ownership Limitation would be exceeded in connection with a Closing,
the number of shares of Common Stock issuable to the Investor shall be reduced so it does not exceed the Beneficial Ownership Limitation.

 

(h)              
PRINCIPAL MARKET REGULATION. Unless the Company has obtained the approval of its stockholders for the issuance of more than
6,601,731 shares of Common Stock pursuant to this Agreement, the Company shall have no right to issue and the Investor shall have no obligation
to purchase any Purchase Notice Shares if the issuance of aggregate Purchase Notice Shares would exceed 6,601,731 shares of Common Stock
(the “Exchange Cap”). The Exchange Cap shall be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split (including forward and reverse), or other similar transaction. 

 

(i)                
NO KNOWLEDGE. The Company shall have no knowledge of any event more likely than not to have the effect of causing the effectiveness
of the Base Registration Statement to be suspended or the Prospectus or any Prospectus Supplement thereto failing to meet the requirement
of Sections 5(b) or 10 of the Securities Act (which event is more likely than not to occur within the fifteen (15) Business Days following
the Business Day on which such Purchase Notice is deemed delivered).

 

(j)                
NO VIOLATION OF SHAREHOLDER APPROVAL REQUIREMENT. The issuance of the Purchase Notice Shares shall not violate the shareholder
approval requirements of the Principal Market.

 

(k)              
DWAC ELIGIBLE. The Common Stock must be DWAC Eligible and not subject to a DTC “chill”.

 

(l)                
SEC DOCUMENTS. All reports, schedules, registrations, forms, statements, information and other documents required to have
been filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within
the applicable time periods prescribed for such filings under the Exchange Act  (including,
if applicable, any extension period permitted under Rule 12b-25 of the Exchange Act). To the best knowledge of the Company,
as of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and other federal laws, rules and regulations applicable to such SEC Documents, and none of the SEC Documents
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading.

 

    16

     

    

 

ARTICLE VIII

LEGENDS

 

Section 8.1              
NO RESTRICTIVE STOCK LEGEND. No restrictive stock legend shall be placed on the share certificates representing the Purchase
Notice Shares, except that a restrictive legend may be placed on such share certificates for Purchase Notice Shares that are subject to
a “lock-up” arrangement pursuant to Section 6.5.

 

Section 8.2           
INVESTOR’S COMPLIANCE. Nothing in this Article VIII shall affect in any way the Investor’s obligations hereunder
to comply with all applicable securities laws upon the sale of the Common Stock.

 

ARTICLE
IX

indemnification

 

Section 9.1           
Each Party (an “Indemnifying Party”) agrees to indemnify and hold harmless the other Party along with its officers,
directors, employees, and authorized agents (an “Indemnified Party”) from and against any claim or suite by third parties
for Damages resulting from or arising out of (i) any misrepresentation, breach of warranty or nonfulfillment of or failure to perform
any covenant or agreement on the part of the Indemnifying Party contained in this Agreement, (ii) any untrue statement or alleged untrue
statement of a material fact contained in the Base Registration Statement or any post-effective amendment thereof or Prospectus or Prospectus
Supplement, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements
therein not misleading, (iii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus
covering the offering and sale of the Securities or contained in the final prospectus covering the offering and sale of the Securities
(each as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged
omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which
the statements therein were made, not misleading, or (iv) any violation by the Indemnifying Party of the Securities Act, the Exchange
Act, any applicable state securities law or any applicable rule or regulation under the Securities Act, the Exchange Act or any state
securities law, as such Damages are incurred by the Indemnified Party except to the extent that such Damages result primarily from the
Indemnified Party’s failure to perform any covenant or agreement contained in this Agreement or the Indemnified Party’s negligence,
recklessness or willful misconduct; provided, however, that the foregoing indemnity agreement shall not apply to any Damages of the Investor
to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged
omission made by the Company in reliance upon and in conformity with information furnished to the Company by the Investor for use in the
Base Registration Statement, any post-effective amendment thereof, Prospectus, Prospectus Supplement thereto, or any preliminary prospectus
or final prospectus covering the offering and sale of the Securities (each as amended or supplemented).

 

    17

     

    

 

ARTICLE X

MISCELLANEOUS

 

Section 10.1       
FORCE MAJEURE. No Party shall be liable for any failure to fulfill its obligations hereunder due to causes beyond its reasonable
control, including but not limited to acts of God, epidemic or pandemic, natural disaster, labor disturbances, terrorist attack, riots
or wars, and any action taken, or restrictions or limitations imposed, by government or public authorities.

 

Section 10.2       
GOVERNING LAW. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware
without regard to the principles of conflicts of law.

 

Section 10.3       
ASSIGNMENT. The Transaction Documents shall be binding upon and inure to the benefit of the Company and the Investor and
their respective successors. Neither any of the Transaction Documents nor any rights of the Investor or the Company hereunder may be assigned
by either Party to any other Person without the written consent of the non-assigning Party.

 

Section 10.4       
NO THIRD-PARTY BENEFICIARIES. This Agreement is intended for the benefit of the Company and the Investor and their respective
successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

Section 10.5       
TERMINATION. This Agreement shall automatically terminate on the earlier of (i) the end of the Commitment Period; or (ii)
the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences
a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of its property or the Company
makes a general assignment for the benefit of its creditors.

 

Section 10.6       
ENTIRE AGREEMENT. The Transaction Documents, together with the exhibits thereto, contain the entire understanding of the
Company and the Investor with respect to the matters covered herein and therein and supersede all prior agreements and understandings,
oral or written, with respect to such matters.

 

Section 10.7       
FEES AND EXPENSES. Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each
Party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such Party incidental to the negotiation, preparation, execution, delivery and performance of the Transaction Documents. The Company
shall pay the Clearing Costs associated with each Closing, (including any reasonable and documented fees required for same-day processing
of any instruction letter delivered by the Company), applicable stamp taxes, and other applicable taxes and duties levied on the Company
in connection with the delivery of any Securities to the Investor.

 

    18

     

    

 

Section 10.8       
COUNTERPARTS AND EXECUTION. The Transaction Documents may be executed in multiple counterparts, each of which may be executed
by less than all of the Parties and shall be deemed to be an original instrument which shall be enforceable against the Parties actually
executing such counterparts and all of which together shall constitute one and the same instrument. The Transaction Documents may be delivered
to the other Party hereto by email of a copy of the Transaction Documents bearing the signature of the Party so delivering the Transaction
Documents. The Parties agree that this Agreement shall be considered signed when the signature of a Party is delivered by .PDF, DocuSign
or other generally accepted electronic signature. Such .PDF, DocuSign, or other generally accepted electronic signature shall be treated
in all respects as having the same effect as an original signature. The signatories to this Agreement each represent and warrant that
they are duly authorized by the Parties with the power and authority to bind the Parties to the terms and conditions thereof.

 

Section 10.9       
SEVERABILITY. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that such
severability shall be ineffective if it materially changes the economic benefit of this Agreement to any Party.

 

Section 10.10   
 FURTHER ASSURANCES. Each Party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other Party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

Section 10.11   
NOT TO BE CONSTRUED AGAINST DRAFTER. The Parties acknowledge that they have had an adequate opportunity to review each and
every provision contained in this Agreement and to submit the same to legal counsel for review and comment. The Parties agree with each
and every provision contained in this Agreement and agree that the rule of construction that a contract be construed against the drafter,
if any, shall not be applied in the interpretation and construction of this Agreement.

 

Section 10.12   
TITLE AND SUBTITLES. The titles and subtitles used in this Agreement are used for the convenience of reference and are not
to be considered in construing or interpreting this Agreement.

 

Section 10.13   
AMENDMENTS; WAIVERS. No provision of this Agreement may be amended other than by a written instrument signed by both Parties
hereto and no provision of this Agreement may be waived other than in a written instrument signed by the Party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other
right, power or privilege.

 

Section 10.14   
PUBLICITY. The Company and the Investor shall consult with each other in issuing any press releases or otherwise making
public statements with respect to the transactions contemplated hereby and no Party shall issue any such press release or otherwise make
any such public statement, other than as required by law or for legal compliance, without the prior written consent of the other Party,
which consent shall not be unreasonably withheld or delayed, except that no prior consent shall be required if such disclosure is required
by law, in which such case the disclosing Party shall provide the other Party with prior notice of such public statement. The Investor
acknowledges that the Transaction Documents may be deemed to be “material contracts,” as that term is defined by Item
601(b)(10) of Regulation S-K, and that the Company may therefore be required to file such documents as exhibits to reports or registration
statements filed under the Securities Act or the Exchange Act. The Investor further agrees that the status of such documents and materials
as material contracts shall be determined solely by the Company, in consultation with its counsel.

 

    19

     

    

 

Section 10.15   
DISPUTE RESOLUTION.

 

		(a)	Average Daily Trading Volume, Purchase Notice LimitATION, OR
VWAP.

 

(i)            In
the case of a dispute relating to the Average Daily Trading Volume, Purchase Notice Limitation, or VWAP (as the case may be) (including,
without limitation, a dispute relating to the determination of any of the foregoing), the Company or the Investor (as the case may be)
shall submit the dispute to the other Party via facsimile or electronic mail within five (5) Business Days after the Party learned of
the circumstances giving rise to such dispute. If the Investor and the Company are unable to promptly resolve such dispute relating to
such Average Daily Trading Volume, Purchase Notice Limitation, or VWAP (as the case may be), at any time after the second (2nd) Business
Day following such initial notice by the Company or the Investor (as the case may be) of such dispute to the Company or the Investor
(as the case may be), then the Company and the Investor may select an independent, reputable investment bank as mutually agreed upon
to resolve such dispute. In the event that the Parties cannot agree upon such an investment bank within ten (10) Business Days of the
date of the initial notice, the Parties shall submit the dispute to arbitration pursuant to Section 10.15(b).

 

(ii)            The Investor and the Company shall each deliver to such investment bank referenced in Section 10.15(a)(i) (A) a copy of the initial
dispute submission so delivered in accordance with the above and (B) written documentation supporting its position with respect to such
dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5th) Business Day immediately following the date on which
such investment bank was selected (the “Dispute Submission Deadline”) (the documents referred to in the immediately
preceding clauses (A) and (B) are collectively referred to herein as the “Required Dispute Documentation”) (it being
understood and agreed that if either the Investor or the Company fails to so deliver all of the Required Dispute Documentation by the
Dispute Submission Deadline, then the Party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled
to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank with respect
to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered
to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Investor
or otherwise requested by such investment bank, neither the Company nor the Investor shall be entitled to deliver or submit any written
documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation).

 

    20

     

    

 

(iii)           The Company and the Investor shall cause such investment bank referenced in Section 10.15(a)(i) to determine the resolution of
such dispute and notify the Company and the Investor of such resolution no later than ten (10) Business Days immediately following the
Dispute Submission Deadline. The reasonable and documented fees and expenses of such investment bank shall be borne by the non-prevailing
Party, and such investment bank’s resolution of such dispute shall be final and binding upon all Parties. The terms of this Agreement
and each other applicable Transaction Document shall serve as the basis for the selected investment bank’s resolution of the applicable
dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like
that such investment bank determines are required to be made by such investment bank in connection with its resolution of such dispute
and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Agreement
and any other applicable Transaction Documents.

 

(iv)          Both the Company and the Investor expressly acknowledge and agree that (i) this Section 10.15(a) constitutes an agreement to arbitrate
between the Company and the Investor (and constitutes an arbitration agreement) under § 5701, et seq. of the Delaware Code Title
10 with respect to the dispute described in Section 10.15(a)(i) and that both the Company and the Investor are authorized to apply for
an order to compel arbitration pursuant to Delaware Code Title 10 § 5703 in order to compel compliance with this Section 10.15(a).

 

(b)           
ARBITRATION. Subject to Section 10.15(a), any dispute, controversy or claim arising out of or relating to this Agreement
or any Transaction Document (including whether any such dispute is arbitrable), shall be determined by arbitration administered by the
American Arbitration Association (“AAA”) pursuant to the AAA Commercial Arbitration Rules in effect at the time of
the filing of the relevant arbitration demand. The Parties will cooperate with the AAA through its case management staff in choosing a
single arbitrator from the AAA’s list of neutral arbitrators and in otherwise proceeding with the arbitration. Any award resulting
from an arbitration initiated pursuant to this Agreement shall be enforceable in courts of applicable jurisdiction. The Parties consent
to the jurisdiction of the Chancery Court of the State of Delaware and the United States District Court for the District of Delaware for
all purposes in connection with any such arbitration. The Parties further waive any right to any jury trial in any action, and as to all
claims hereunder. Any arbitration pursuant to this section shall be governed by the Federal Arbitration Act. Except as may be required
by law, neither a Party nor the arbitrator may disclose the content or results of any arbitration proceeding conducted pursuant to this
Agreement without the prior written consent of both Parties. Each Party will be responsible for 50% of any administrative costs imposed
by the AAA and the arbitrator’s fees. Each Party may choose, at its own expense, to retain a court reporter for the arbitration
hearing. If both Parties decide to use a court reporter for the arbitration hearing, the Parties shall jointly retain a court reporter
and split evenly the court reporter’s fees. The prevailing Party in any arbitration conducted pursuant to this Agreement shall be
entitled to recover from the other Party its reasonable and documented attorneys’ fees and costs, so long as no Party shall be
required to provide any documentation or information to the extent that the provision thereof would undermine or otherwise jeopardize
attorney-client privilege.

 

(c)           The Company and the Investor agree that all dispute resolution proceedings in accordance with this Section 10.15 may be conducted
in a virtual setting.

 

    21

     

    

 

Section 10.16   
NOTICES. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall
be in writing and, unless otherwise specified herein, shall be (a) personally served, (b) delivered by reputable air courier service with
charges prepaid for next Business Day delivery, or (c) transmitted by hand delivery, or email as a PDF (with read receipt or a written
confirmation of delivery or receipt), addressed as set forth below or to such other address as such Party shall have specified most recently
by written notice given in accordance herewith. Any notice or other communication required or permitted to be given hereunder shall be
deemed effective upon hand delivery or delivery by email at the address designated below (if delivered on a Business Day during normal
business hours where such notice is to be received), or the first Business Day following such delivery (if delivered other than on a Business
Day during normal business hours where such notice is to be received).

 

The addresses for such communications
shall be:

 

If to the Company:

Address: 350 Technology Drive, Pittsburgh, PA

Telephone:
(412) 763-3350

E-mail: tbranning@neubasetherapeutics.com

  

If to the Investor:

Address: 405 Lexington Ave., 9th
Floor, New York, NY 10174

Telephone:
(917) 793-1173

E-mail: operations@alumnicapital.com

 

Either Party hereto may from time to time change
its address or email for notices under this clause by giving prior written notice of such changed address to the other Party hereto.

 

[Signature Page Follows]

 

    22

     

    

 

IN WITNESS WHEREOF, the
Parties have caused this Agreement to be duly executed by their respective officers thereunto duly authorized as of the Execution Date.

  

	 	NEUBASE THERAPEUTICS, INC.
	 	  
	 	By: 	/s/ Dietrich Stephan
	 	 
	 	Name: Dietrich Stephan
	 	Title:   Chief Executive Officer
	 	Date:   December 28, 2022
	 	  
	 	ALUMNI CAPITAL LP
	 	 
	 	By: Alumni Capital GP LLC
	 	Its: General Partner
	 	 
	 	By: 	/s/ Ashkan Mapar
	 	 
	 	Name: Ashkan Mapar
	 	Title:   Manager
	 	Date:   December 28, 2022

 

    23

     

    

  

EXHIBIT A

 

FORM OF PURCHASE NOTICE

 

TO: ALUMNI CAPITAL LP

 

We refer to the Purchase Agreement,
dated as of December 27, 2022 (the “Agreement”), entered into by and between NEUBASE THERAPEUTICS, INC., and you. Capitalized
terms defined in the Agreement shall, unless otherwise defined herein, have the same meaning when used herein.

 

We hereby:

 

1) Give you notice that we require you to purchase
__________ Purchase Notice Shares; and

 

2) Certify that, as of the date hereof, the conditions
set forth in Section 7 of the Agreement are satisfied.

 

	 	NEUBASE THERAPEUTICS, INC.
	 	 
	 	By:	                      
	 	 
	 	Name: Dietrich Stephan
	 	Title:   Chief Executive Officer
	 	Date:

 

    24EX-10.1

 Exhibit 10.1 

PROMISSORY NOTE 
  

			
	$654,000	  	As of December 28, 2022

 Slam Corp. (“Maker”) promises to pay to the order of Slam Sponsor, LLC or its successors or assigns
(“Payee”) the principal sum of six hundred fifty-four thousand dollars ($654,000) in lawful money of the United States of America, on the terms and conditions described below. 

1. Principal. The principal balance of this Note shall be repayable on the consummation of the Maker’s initial merger, stock
exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (a “Business Combination”). Payee understands that if a Business Combination is not
consummated, this Note will not be repaid and all amounts owed hereunder will be forgiven except to the extent that the Maker has funds available to it outside of its trust account established in connection with its initial public offering. 

2. Interest. No interest shall accrue on the unpaid principal balance of this Note. 

3. Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any
sum due under this Note, including (without limitation) reasonable attorneys’ fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note. 

4. Events of Default. The following shall constitute Events of Default: 

(a) Failure to Make Required Payments. Failure by Maker to pay the principal of this Note within five (5) business days following
the date when due. 
 (b) Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under the Federal Bankruptcy
Code, as now constituted or hereafter amended, or any other applicable federal or state bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver,
liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its
debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing. 
 (c) Involuntary
Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of maker in an involuntary case under the Federal Bankruptcy Code, as now or hereafter constituted, or any other applicable
federal or state bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days. 

5. Remedies. 
 (a)
Upon the occurrence of an Event of Default specified in Section 4(a), Payee may, by written notice to Maker, declare this Note to be due and payable, whereupon the principal amount of this Note, and all other amounts payable thereunder, shall
become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding. 

(b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of, and all other sums
payable with regard to, this Note shall automatically and immediately become due and payable, in all cases without any action on the part of Payee. 

6. Conversion. Upon consummation of a Business Combination, the Payee shall have the option, but not the obligation, to convert the
principal balance of this Note, in whole or in part at the option of the Payee, into Private Placement Warrants (as defined in that certain Warrant Agreement, dated February 25, 2021, by and between the Maker and Continental Stock
Transfer & Trust Company), at a price of $1.50 per Private Placement Warrant. As promptly after notice by Payee to Maker to convert the principal balance of this Note, which must be made at least 24 hours prior to the consummation of the
Business Combination, as reasonably practicable and after Payee’s surrender of this Note, Maker shall have issued and delivered to Payee, without any charge to Payee, a warrant certificate or certificates (issued in the name(s) requested by
Payee), or made appropriate book-entry notation on the books and records of the Maker, for the number of Warrants of Maker issuable upon the conversion of this Note. 

 7. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note
waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might
accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of
execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any
such writ in whole or in part in any order desired by Payee. 
 8. Unconditional Liability. Maker hereby waives all notices in
connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any
manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the
payment or other provisions of this Note, and agree that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to them or affecting their liability hereunder. 

9. Notices. Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt
requested, (ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery, (iv) sent by telefacsimile or (v) sent
by e-mail, to the following addresses or to such other address as either party may designate by notice in accordance with this Section: 

If to Maker: 
 Slam Corp. 

55 Hudson Yards, 47th Floor, Suite C 

New York, New York 10001 
 If to
Payee: 
 Slam Sponsor, LLC 

55 Hudson Yards, 47th Floor, Suite C 

New York, New York 10001 
 Notice shall be
deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a telefacsimile transmission confirmation, (iii) the date on which
an e-mail transmission was received by the receiving party’s on-line access provider, (iv) the date reflected on a signed delivery receipt
or (v) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service. 
 10. Trust
Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from the trust account established in which proceeds of
the Makers initial public offering of securities (“IPO”) (including the deferred underwriters discounts and commissions) and proceeds of the sale of the warrants issued in a private placement which occurred in connection with the
consummation of the IPO are deposited, as described in greater detail in the registration statement and prospectus filed with the Securities and Exchange Commission in connection with the IPO, and hereby agrees not to seek recourse, reimbursement,
payment or satisfaction for any Claim against the trust account for any reason whatsoever. 
 11. Construction. This Note shall be
construed and enforced in accordance with the domestic, internal law, but not the law of conflict of laws, of the State of New York. 

 12. Severability. Any provision contained in this Note which is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any
jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 [Remainder of Page Intentionally
Left Blank] 

 IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by
its Chairman as of the day and year first above written. 
  

			
	Slam Corp.
		
	By:	 	 /s/ Himanshu Gulati

	Name:	 	Himanshu Gulati
	Title:	 	Chairman

  

					
	Agreed and Acknowledged:
	
	Slam Sponsor, LLC
	a Cayman Islands limited liability company
		
	By:	 	 /s/ Himanshu Gulati

		 	Name:	 	Himanshu Gulati
		 	Title:	 	Authorized Signatory

 [Signature Page to Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]